Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$14.58
+4.1%
$13.49
$9.83
$17.75
$131.48M0.918,288 shs6,882 shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$9.81
+0.1%
$9.79
$8.06
$18.75
$131.14M1.7446,310 shs29,704 shs
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$1.87
-3.1%
$2.13
$1.61
$11.20
$119.73M0.93769,122 shs442,387 shs
MAAQ
Mana Capital Acquisition
$3.95
-6.8%
$1.04
$5.35
$10.25
$32.09MN/A33,075 shs68,563 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
0.00%+6.89%+5.27%-5.57%+4.14%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
0.00%+0.72%-6.03%-17.91%-27.33%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
0.00%-5.56%-21.10%-41.38%-76.33%
MAAQ
Mana Capital Acquisition
-6.84%+2.86%+763.77%+682.95%+464.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
4.3211 of 5 stars
3.75.00.00.01.63.33.1
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
1.1833 of 5 stars
3.50.00.00.00.03.30.0
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
2.1086 of 5 stars
3.61.00.00.04.31.70.0
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
3.33
Buy$20.5040.60% Upside
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
3.00
Buy$39.00297.55% Upside
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3.10
Buy$20.43992.44% Upside
MAAQ
Mana Capital Acquisition
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MAAQ, GLSI, FTLF, and LRMR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/21/2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$38.00 ➝ $39.00
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$13.00 ➝ $10.00
3/17/2025
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$63.86M2.14$0.77 per share19.05$3.04 per share4.80
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.52 per shareN/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/A$1.86 per shareN/A
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$5.30M$0.8417.2513.25N/A13.38%28.03%15.13%N/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$8.89M-$1.26N/AN/AN/AN/A-185.12%-164.27%8/12/2025 (Estimated)
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$36.95M-$1.49N/AN/AN/AN/A-35.87%-32.37%8/6/2025 (Estimated)
MAAQ
Mana Capital Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A

Latest MAAQ, GLSI, FTLF, and LRMR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2025Q1 2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.24-$0.25-$0.01-$0.25N/AN/A
5/15/2025Q1 2025
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$0.24$0.20-$0.04$0.20N/AN/A
4/30/2025Q1 2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.42-$0.46-$0.04-$0.46N/AN/A
4/15/2025Q4 2024
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.21-$0.61-$0.40-$0.61N/AN/A
3/27/2025Q4 2024
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$0.22$0.21-$0.01N/AN/AN/A
3/24/2025Q4 2024
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.29-$0.45-$0.16-$0.45N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
N/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/AN/A
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
0.28
1.50
0.64
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
6.91
6.91
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/A
13.10
13.10
MAAQ
Mana Capital Acquisition
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
2.32%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
91.92%
MAAQ
Mana Capital Acquisition
68.44%
CompanyEmployeesShares OutstandingFree FloatOptionable
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
209.39 million3.56 millionNot Optionable
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
313.37 million6.35 millionNot Optionable
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3064.03 million61.57 millionOptionable
MAAQ
Mana Capital Acquisition
18.13 millionN/ANot Optionable

Recent News About These Companies

Decentraland (CRYPTO: MANA)

New MarketBeat Followers Over Time

Media Sentiment Over Time

FitLife Brands stock logo

FitLife Brands NASDAQ:FTLF

$14.58 +0.58 (+4.14%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$14.45 -0.13 (-0.89%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

Greenwich LifeSciences stock logo

Greenwich LifeSciences NASDAQ:GLSI

$9.81 +0.01 (+0.10%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$9.82 +0.01 (+0.15%)
As of 05/23/2025 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Larimar Therapeutics stock logo

Larimar Therapeutics NASDAQ:LRMR

$1.87 -0.06 (-3.11%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$1.93 +0.06 (+3.42%)
As of 05/23/2025 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Mana Capital Acquisition NASDAQ:MAAQ

$3.95 -0.29 (-6.84%)
As of 05/23/2025

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.